News
Effective July 25, 2021: Removal of Prior Authorization Requirement for Cell-free Fetal DNA Testing
Date: 07/01/21
Effective July 25, 2021, Ambetter from Superior HealthPlan will no longer require prior authorization for cell-free fetal DNA testing for members. Below is the listing of Current Procedural Terminology (CPT) codes included in this change to the prior authorization requirements.
CPT Codes | Description |
|---|---|
81420 | Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18 and 21. |
81507 | Fetal aneuploidy (trisomy 21, 18 and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy. |
To review prior authorization requirements, please visit Ambetter's Prior Authorization Requirements for Health Insurance Marketplace webpage.
For questions or additional information, contact Ambetter’s Prior Authorization department at 1-800-218-7508.